Johnson & Johnson (JNJ) fair value analysis

S&P 500 · Updated 2026-09-07

Johnson & Johnson is a diversified healthcare company that develops, manufactures, and markets pharmaceuticals, medical devices, and consumer health products across multiple therapeutic areas and disease categories. The company operates globally with a presence in numerous countries across North America, Europe, Asia-Pacific, Latin America, and other regions worldwide.

Forward Fair Value verdict

Overvalued

Based on TickrTrends' weekly Forward Fair Value model, JNJ is trading at more than a 25% premium to estimated fair value.

JNJ currently ranks #110 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.

Last price: $275.23
Sector: Healthcare
12-month range: $185.08–$271.19

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: F
Leverage: Low
Margin trend: Contracting
Revenue growth: Modest
RSI zone: Neutral
52-week position: The top quarter of its range
DCF cross-check: Overvalued

What our data shows for JNJ

Our model validated 17 trailing price-to-earnings windows for JNJ, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $185.08–$271.19.
The 14-day relative strength index sits at a neutral 64.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for JNJ
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent JNJ news

TickrTrends' derived news-sentiment signal for JNJ is currently leaning positive, computed from recent coverage.

Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know (zacks.com, 2026-09-08)
TickrTrends take: Johnson & Johnson's underperformance relative to the broader market occurs within a context where TickrTrends currently assesses the stock as overvalued. For investors focused on valuation metrics, this divergence between JNJ's decline and overall market movement warrants attention to whether the company's fundamentals are adjusting to justify current pricing or whether the gap may narrow further. Given JNJ's position in the Healthcare sector, monitoring how the stock's valuation multiple responds to this weakness relative to sector peers will be important for understanding whether the overvaluation assessment may shift.
[DowJonesToday]Dow Jones Industrial Average Slumps as Economic Uncertainty Weighs on Blue-Chip Stocks (thestockmarketwatch.com, 2026-09-08)
Why I think this ASX ETF could be a strong buy today (raskmedia.com.au, 2026-09-08)
TickrTrends take: Johnson & Johnson faces a valuation assessment of Overvalued according to TickrTrends, which provides relevant context for investors evaluating the Healthcare sector company. The headline's focus on ETF opportunities underscores why individual security valuations matter, as investors considering fund exposure to healthcare names should understand the valuation positioning of major holdings like JNJ. Valuation-focused readers should monitor whether JNJ's current overvalued status reflects temporary market conditions or fundamental concerns that could affect its performance within broader healthcare investment vehicles.

What people are saying

Follow the JNJ conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is JNJ stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), JNJ is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.

What is JNJ's TickrTrends verdict?

JNJ's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.

How does JNJ compare to other Healthcare stocks?

JNJ ranks #110 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is JNJ overbought or oversold?

JNJ's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

JNJ vs ACAD · JNJ vs ALKS · JNJ vs AMGN · JNJ vs CDNA · JNJ vs DGX